KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Interest Expenses (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Interest Expenses data on record, last reported at $3.9 million in Q4 2025.

  • For Q4 2025, Interest Expenses fell 16.84% year-over-year to $3.9 million; the TTM value through Dec 2025 reached $17.4 million, up 5.29%, while the annual FY2025 figure was $17.4 million, 5.29% up from the prior year.
  • Interest Expenses reached $3.9 million in Q4 2025 per PCRX's latest filing, down from $4.3 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $11.0 million in Q4 2022 and bottomed at $3.3 million in Q1 2024.
  • Average Interest Expenses over 5 years is $6.3 million, with a median of $4.7 million recorded in 2024.
  • Peak YoY movement for Interest Expenses: surged 47.59% in 2021, then crashed 69.31% in 2023.
  • A 5-year view of Interest Expenses shows it stood at $10.4 million in 2021, then grew by 5.93% to $11.0 million in 2022, then tumbled by 69.31% to $3.4 million in 2023, then soared by 38.13% to $4.7 million in 2024, then fell by 16.84% to $3.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $3.9 million in Q4 2025, $4.3 million in Q3 2025, and $4.7 million in Q2 2025.